Overcoming Obstacles to the Effective Immunotherapy of High-Grade Gliomas
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 277
Special Issue Editor
Interests: molecular pathology; neuropathology; immuno-oncology; cancer genomics; metabolomics; proteomics; signaling pathways; spatial transcriptomics; targeted therapy; immunotherapy
Special Issue Information
Dear Colleagues,
Although immunotherapy has demonstrated remarkable clinical efficacy in subsets of patients with refractory tumors such as advanced melanoma, to date, trials of immunotherapy of high-grade glioma (HGG) patients (WHO Classification 2021) have failed to produce substantial clinical benefits. Major limitations in developing effective immunotherapy for adult and pediatric-type HGGs include our incomplete understanding of the molecular heterogeneity and spatial–temporal evolution of tumor and immune cells and their nutrients and products in HGGs and the mechanisms adopted by HGGs to evade immune surveillance and cause therapeutic resistance. As innovative, high-dimensional technologies such as spatially resolved transcriptomics, proteomics, and metabolomics are becoming available, they may provide new insights into HGG’s cellular organization, functions, and interactions in their morphological contexts. Eventually, the identification of immunologic subtypes of HGGs could help to promote the design of effective immunotherapies and facilitate the optimal selection of responsive patients.
This Special Issue aims to advance our understanding of the mechanisms of immune evasion by adult and pediatric-type HGGs as they relate to the development of immunotherapy. We invite investigators to contribute research articles, review articles, and short communications that will address the themes mentioned above. Since the International Journal of Molecular Sciences is a journal of molecular science, clinical studies or preclinical glioma model studies must be accompanied by molecular mechanistic analyses to be suitable for publication in the journal.
Dr. Jean-Pierre Gagner
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adult-type diffuse glioma
- glioblastoma
- high-grade glioma
- immuno-oncology
- immunotherapy
- metabolomics
- pediatric-type diffuse high grade glioma
- spatial transcriptomics
- tumor immune microenvironment
- tumor immune evasion
